These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6285557)

  • 1. In vivo antileishmanial properties of pentavalent antimonial compounds.
    Neal RA; Matthews PJ
    Trans R Soc Trop Med Hyg; 1982; 76(2):284. PubMed ID: 6285557
    [No Abstract]   [Full Text] [Related]  

  • 2. An in vitro micromethod for drug sensitivity testing of Leishmania.
    Jackson JE; Tally JD; Tang DB
    Am J Trop Med Hyg; 1989 Sep; 41(3):318-30. PubMed ID: 2552851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani.
    Chakraborty AK; Majumder HK
    Biochem Biophys Res Commun; 1988 Apr; 152(2):605-11. PubMed ID: 2835038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
    Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D
    Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucantime resistant Leishmania promastigotes are sensitive to pentostam.
    Moreira ES; Guerra JB; Petrillo-Peixoto Mde L
    Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis.
    Marsden PD; Sampaio RN; Carvalho EM; Veiga JP; Costa JL; Llanos-Cuentas EA
    Am J Trop Med Hyg; 1985 Jul; 34(4):710-3. PubMed ID: 2992304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
    Veiga JP; Rosa TT; Kimachi T; Wolff ER; Sampaio RN; Gagliardi AR; Junqueira Júnior LF; Costa JM; Marsden PD
    Rev Inst Med Trop Sao Paulo; 1985; 27(6):298-302. PubMed ID: 3014634
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimony oxidation states in antileishmanial drugs.
    Franco MA; Barbosa AC; Rath S; Dorea JG
    Am J Trop Med Hyg; 1995 May; 52(5):435-7. PubMed ID: 7771610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials.
    Veiga JP; Wolff ER; Sampaio RN; Marsden PD
    Lancet; 1983 Sep; 2(8349):569. PubMed ID: 6136717
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
    Roberts WL; Berman JD; Rainey PM
    Antimicrob Agents Chemother; 1995 Jun; 39(6):1234-9. PubMed ID: 7574507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy.
    Jackson JE; Tally JD; Ellis WY; Mebrahtu YB; Lawyer PG; Were JB; Reed SG; Panisko DM; Limmer BL
    Am J Trop Med Hyg; 1990 Nov; 43(5):464-80. PubMed ID: 2173431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis.
    Martinez S; Looker DL; Berens RL; Marr JJ
    Am J Trop Med Hyg; 1988 Sep; 39(3):250-5. PubMed ID: 2845824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
    Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
    Grogl M; Thomason TN; Franke ED
    Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
    Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG
    PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate.
    Berman JD; Waddell D; Hanson BD
    Antimicrob Agents Chemother; 1985 Jun; 27(6):916-20. PubMed ID: 2411217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of In vitro and In vivo Drug Efficacy Over Leishmania tropica: A Pilot Study.
    Özbilgin A; Çavuş İ; Yıldırım A; Kaya T; Ertabaklar H
    Turkiye Parazitol Derg; 2018 Mar; 42(1):11-19. PubMed ID: 29780014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary agent for leishmaniasis.
    Berman JD
    Am J Trop Med Hyg; 1988 May; 38(3):652. PubMed ID: 2856321
    [No Abstract]   [Full Text] [Related]  

  • 20. Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals.
    Mottram JC; Coombs GH
    Exp Parasitol; 1985 Apr; 59(2):151-60. PubMed ID: 2982638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.